Human Papilloma Virus IgG ELISA kit

Name: Human Papilloma Virus IgG ELISA kit
SKU: DEIA-F678S
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

plasma, serum

Species Reactivity

Human

Detection Method

iELISA

Intended Use

Enzyme Immuno Assay (EIA) for determination of IgG class antibodies to Human Papilloma Virus (or HPV) in human plasma and sera.
The product is supplied for research purpose only. It is not for use in the diagnosis or for the follow-up of patients administered with the vaccines containing HPV antigens.

Contents of Kit

1. Microplate: 12 strips × 8 breakable microwells coated with recombinant VLP's derived from HPV Type 6, 11, 16 E, 18. Plates are sealed into a bag with desiccant. Allow the microplate to reach room temperature before opening; reseal unused strips in the bag with desiccant and store at 4°C.
2. Negative Control: 1×4.0 mL/vial. Ready to use and pale yellow color coded. Contains human serum negative for IgG anti HPV, 2% casein, 10 mM Na-citrate buffer pH 6.0 +/-0.1, 0.1% Tween 20, 0.09% Na-azide and 0.1% Kathon GC as preservatives.
3. Positive Control: 1×4.0 mL/vial. Ready to use and dark green color coded. Contains human serum positive for IgG anti HPV, 2% casein, 10 mM Na-citrate buffer pH 6.0 ± 0.1, 0.1% Tween 20, 0.09% Na-azide and 0.1% Kathon GC as preservatives.
4. 20×Wash buffer concentrate: 1×60 mL/bottle. 20× concentrated solution. Once diluted, the wash solution contains 10 mM phosphate buffer pH 7.0+/-0.2, 0.05% Tween 20 and 0.05% Kathon GC.
5. Enzyme Conjugate: 1×16 mL/vial. Ready to use and red colour coded. It contains Horseradish peroxidase conjugated polyclonal antibodies to human IgG, 5% BSA, 10 mM Tris buffer pH 6.8+/-0.1, 0.1% Kathon GC and 0.02% gentamicine sulphate as preservatives.
6. Chromogen/Substrate: 1×16 mL/vial. It contains 50 mM citrate-phosphate buffer pH 3.5-3.8, 4% dimethylsulphoxide, 0.03% tetra-methylbenzidine (or TMB) and 0.02% hydrogen peroxide (or H₂O₂).
Note: To be stored protected from light as sensitive to strong illumination.
7. Sulphuric Acid: H₂SO₄ 0.3M, 1×15 mL/vial. It contains 0.3 M H₂SO₄ solution.
8. Specimen Diluent: 2×60mL/vial. It contains 2% casein, 10 mM Na-citrate buffer pH 6.0 +/-0.1, 0.1% Tween 20, 0.09% Na-azide and 0.1% Kathon GC as preservatives. To be used to dilute the sample.
9. Plate sealing foils 2
10. Package insert 1

Storage

2°C to 8°C

Citations

Have you cited DEIA-F678S in a publication? Let us know and earn a reward for your research.

Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults

Vania Giacomet, Francesca Penagini, Daria Trabattoni, Alessandra Viganò, Veronica Rainone, Giada Bernazzani, Claudia Maria Bonardi, Mario Clerici, Giorgio Bedogni, Gian Vincenzo Zuccotti

Vaccine2014 SepPubMed ID: 25149430Read Article

Applications: ELISA
Reactive species: Human
"Abstract: Human papillomavirus (HPV) infection is highly prevalent and can lead to cancer; the development of safe and efficacious vaccines for HPV is a major public health concern. The two licensed HPV vaccines contain recombinant virus-like particles of HPV 16 and 18; one of such vaccines also protects against HPV types 6 and 11 which cause genital warts. We determined safety and immunogenicity of quadrivalent HPV vaccine in HIV-infected and HIV-negative adolescents and young adults, aged 13-27 years. The seroconversion rate, assessed by antibody titers, 1 month after the administration of the third vaccine dose was 0.85 (95% CI 0.75-0.95) in the HIV-infected group and 0.91 (0.83-0.99) in the HIV-negative subjects (p=0.52). The vaccine was generally safe and well tolerated; the most common side effect was local pain and the most frequent systemic side effect was headache. This is the first report on response to HPV vaccination in both female and male HIV-infected adolescents and young adults and highlights that this population may benefit from HPV immunoprophylaxis. Further studies are needed to examine the long term efficacy of this vaccine in HIV-infected individuals."
Article snippet: Antibody titers against HPV types 6, 11, 16 and 18 were measured using a Human Papillomavirus IgG ELISA kit (Creative Diagnostics, NY, NY, USA) according to manufacturer’s instructions.

Anti-HPV IgG titers in HIV-infected and HIV-negative individuals. (Vania Giacomet, <i>et al</i>, 2014)

Figure 1. Anti-HPV IgG titers in HIV-infected and HIV-negative subjects

Documents

pdf COA

pdf SDS

pdf Datasheet

HPV Reagents for Vaccine Research and Immunoassay Development

QA & Reviews

Customer Reviews

References

Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing

INTERNATIONAL JOURNAL OF CANCER

Authors: Green, Leonardo I.; Mathews, Christopher S.; Waller, Jo; Kitchener, Henry; Rebolj, Matejka

Abstract

Attendance at early recall and colposcopy is crucial to attaining the benefits of primary high-risk human papillomavirus (HR-HPV)-based screening. Within the English HPV pilot, we analysed deprivation- and age-related patterns of attendance at colposcopy and 12- and 24-month early recall of HR-HPV positive women screened in 2013 to 2015 (N = 36 466). We fitted logistic regression models for adjusted odds ratios (OR). Despite high overall attendance, area deprivation had a small but significant impact at both early recalls, for example, attendance at 24 months was 86.3% and 83.0% in less vs more deprived areas, respectively (ORadj: 0.76; 95% CI: 0.67-0.87). Older women (>= 30 years) were more likely to attend early recall than younger women (<30 years), for example, attendance at 24 months was 86.1% vs 82.3%, respectively (ORadj: 1.32, 95% CI: 1.16-1.51). Most women attended colposcopy following a baseline referral, with 96.9% attendance among more deprived and 97.8% among less deprived areas (ORadj: 0.70; 95% CI: 0.55-0.88). Differences in colposcopy attendance by deprivation level at 12 and 24 months were of approximately the same magnitude. In conclusion, attendance at early recall and colposcopy was reassuringly high. Although there were statistically significant differences by deprivation and age group, these were small in absolute terms.

ATP synthase modulation leads to an increase of spare respiratory capacity in HPV associated cancers

SCIENTIFIC REPORTS

Authors: Kirschberg, Matthias; Heuser, Sandra; Marcuzzi, Gian Paolo; Hufbauer, Martin; Seeger, Jens Michael; Dukic, Anamaria; Tomaic, Vjekoslav; Majewski, Slawomir; Wagner, Steffen; Wittekindt, Claus; Wuerdemann, Nora; Klussmann, Jens Peter; Quaas, Alexander; Kashkar, Hamid; Akguel, Baki

Abstract

Mucosal and skin cancers are associated with infections by human papillomaviruses (HPV). The manner how viral oncoproteins hijack the host cell metabolism to meet their own energy demands and how this may contribute to tumorigenesis is poorly understood. We now show that the HPV oncoprotein E7 of HPV8, HPV11 and HPV16 directly interact with the beta subunit of the mitochondrial ATP-synthase (ATP5B), which may therefore represent a conserved feature across different HPV genera. By measuring both glycolytic and mitochondrial activity we observed that the association of E7 with ATP5B was accompanied by reduction of glycolytic activity. Interestingly, there was a drastic increase in spare mitochondrial respiratory capacity in HPV8-E7 and an even more profound increase in HPV16-E7 expressing cells. In addition, we could show that ATP5B levels were unchanged in betaHPV positive skin cancers. However, comparing HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas (OPSCC) we noticed that, while ATP5B expression levels did not correlate with patient overall survival in HPV-negative OPSCC, there was a strong correlation within the HPV16-positive OPSCC patient group. These novel findings provide evidence that HPV targets the host cell energy metabolism important for viral life cycle and HPV-mediated tumorigenesis.